Guggenheim analysts revised their price target for Eli Lilly (NYSE:LLY) shares, reducing it to $973.00 from the previous $995 ...
Ozempic, Rybelsus and Wegovy top the list of the newest drugs selected for Medicare Part price negotiation, part of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback